Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device

Sponsor

GlucoVista (Industry)

Overall Status

Unknown status

CT.gov ID

NCT01508065

Collaborator

(none)

Enrollment

Locations

Patients Per Site

Study Details

Study Description

Brief Summary

Adequate glycemic control in patients with Diabetes Mellitus (DM) is a desired therapeutic goal that can be achieved with a true non-invasive device offering the likelihood of continuous glucose monitoring. Currently, glucose is best monitored by measuring capillary blood from the fingertips, from venous/arterial line blood samples and from a daily calibrated Subcutaneous Blood Glucose Monitor (SBGM) which is a source of severe inconvenience and hence, a lack of compliance.

Thus, the need for non-invasive and easy to operate glucose monitoring in DM patients for strict glycemic control cannot be overemphasized.

The Glucometer CGM-305 blood glucose readings are accurate and measure blood glucose with an acceptable mean relative error when compared to acceptable invasive blood glucose measurements.

The primary objectives of the trial are to determine:

The safety of the Glucometer CGM-305 in evaluating blood glucose levels
The accuracy of the Glucometer CGM-305 in evaluating blood glucose levels

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus Type 1	Device: Glucometer CGM-305

Study Design

Study Type:

Observational

Anticipated Enrollment :

20 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device

Study Start Date :

Sep 1, 2012

Actual Primary Completion Date :

Jul 1, 2014

Arms and Interventions

Arm	Intervention/Treatment
controlled type one diabetes mellitus.	Device: Glucometer CGM-305 The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.

Arm

Intervention/Treatment

controlled type one diabetes mellitus.

Device: Glucometer CGM-305

The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.

Outcome Measures

Primary Outcome Measures

Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by mean relative error when compared to venous blood glucose measured by a laboratory device. [will be assessed after second experimental day]
Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by correlation with values measured by glucose hexokinase based assay [will be assessed after second experimental day]
Accuracy of the Glucometer CGM-305 blood glucose readings as evaluated by Clark error grid with measurements of venous blood as the comparing value [will be assessed after second experimental day]

Secondary Outcome Measures

The safety of the Glucometer CGM-305 in evaluating blood glucose levels [The study consists of three days trial, first day lasts an 8-10 hours, second and third days last 4-6 hours.]
Safety will be evaluated in a descriptive manner by recording all adverse events in the patient population by number and severity. The study will evaluate safety by assessing: Device related adverse events: local and systemic effects of the Glucometer CGM-305 including: redness, burns, pain , or other complications. General adverse events: Adverse events not directly related to the Glucometer CGM-305 device but are related to the study procedure (i.e clamping), such as: local infection, blood clot, bleeding, hypoglycemia.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

Type 1 Diabetic patient.
Ages: 18 to 65.
Signed informed consent.
HbA1c of 6%-9% at screening.
Males- not involved in active military duty.
Females-non-child bearing potential or females of child-bearing potential who have a negative pregnancy test (HCG in blood or urine) within 72 hours of informed consent.

Exclusion criteria:

Active systemic or local infection.
Any medical condition that, by the investigator judgment, will increase the risk from Hyper and Hypo-Glycemic experiment: seizures, heart disease, hypoglycemia unawareness etc.
History of malignancy, radiotherapy, or chemotherapy for malignancy (except BCC of the skin)

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hadassah Medical Organization	Jerusalem		Israel	91120
2	Hadassah Medical Organization	Jerusalem		Israel

Sponsors and Collaborators

GlucoVista

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

GlucoVista

ClinicalTrials.gov Identifier:

NCT01508065

Other Study ID Numbers:

gluco01

First Posted:

Jan 11, 2012

Last Update Posted:

Feb 20, 2019

Last Verified:

Feb 1, 2019

Additional relevant MeSH terms:

Diabetes Mellitus, Type 1

Study Results

No Results Posted as of Feb 20, 2019